


Officially launched in 2015 and updated annually, the Continuous Innovation Indicators (CII) is a dynamic online tool that utilizes published clinical trial data to track progress for 12 cancer types over time. CII users can generate evidence-based estimates of prior probabilities for transition between different treatment stages (e.g., advanced, invasive, adjuvant) and evolution of treatments (e.g., refinements, use in combinations, new indications). Data are parsed by disease subtype, therapeutic goal, treatment class, and molecular parameters. Outcome measures include effect sizes from individual trials and Evidence-Scores (E-Scores), a novel metric that tracks cumulative progress over time. Users can:

- Compare evidence between cancers to understand how treatments for one cancer have translated to successes in other cancer research.
- Contextualize long-term trends in specific and general cancer survival and mortality rates.
- Link the CII data with information about regulatory approvals.
- Track and quantify evidence for overall survival (OS) in the pre- and post-approval intervals.
- Predict the long-term value of new cancer treatments at launch based on a combination of historical evidence, regulatory approvals, and current data from registration and other trials.
- Conduct descriptive analyses of evidence supporting any treatment modality for cancers, establishing when the most impactful advances occurred, which patient subgroups experienced the most significant benefit, and how the standard of care has changed over time (Figure 1).



**Figure 1. Immunotherapies for melanoma (red) versus NSCLC (blue) from 1990 to present**

Since its inception, the CII has added considerably to the discourse surrounding policy, specific cancer treatment utility, and determining unmet needs. For example, analyses of historical data in the CII revealed how surrogate endpoints have helped provide timely access to new medicines, and that OS may not be the most appropriate endpoint in all treatment contexts. Analysis of the CII underscored the benefit of using a wide variety of fit-for-purpose evidence types in the approval process ([Brooks et al. 2017](#)).

The CII platform, accessible at [www.scoringprogress.org](http://www.scoringprogress.org), facilitates a more nuanced approach to a treatment's utility over time, reveals unmet needs, and tracks progress within and between cancers. It supports a broad range of value assessment models, leading to improved evidence-based and dynamic estimates of value. The CII is a novel technological application that provides an objective data resource to help stakeholders understand how advances in cancer treatment have historically been achieved and, in turn, informs policy and other efforts to accelerate continuous innovation against cancer. Development of the CII platform by RLA has been supported entirely by Lilly Oncology since 2013.